Which of the following correctly describes the mechanism of action and primary indication of dupilumab in dermatology?
- A Anti-IL-4 receptor alpha (dual IL-4/IL-13 blockade); moderate-to-severe atopic dermatitis ✓
- B Anti-IL-17A; moderate-to-severe psoriasis
- C Anti-IgE; chronic spontaneous urticaria unresponsive to antihistamines
- D Anti-IL-23 (p19); moderate-to-severe plaque psoriasis
Correct answer: A. Anti-IL-4 receptor alpha (dual IL-4/IL-13 blockade); moderate-to-severe atopic dermatitis
Explanation
Dupilumab is a fully human monoclonal antibody targeting the IL-4 receptor alpha subunit (IL-4Rα), which is shared by IL-4 and IL-13 receptors. By blocking this shared receptor, dupilumab simultaneously inhibits both IL-4 and IL-13 signalling — the key Th2 cytokines driving atopic dermatitis inflammation. It is approved for moderate-to-severe atopic dermatitis unresponsive to topical therapy, as well as eosinophilic asthma and nasal polyps. Anti-IgE (omalizumab) is used for chronic urticaria. Guselkumab/risankizumab/secukinumab target IL-23/IL-17.
Reference: Neena Khanna Illustrated Synopsis of Dermatology & STD, 6th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.